Tuesday, November 17, 2026

Methuselah, a startup researching and developing a new cell therapy for heart failure, raises a total of 1.32 billion yen in a Series B round of funding.

Methuselah has raised a total of approximately 1.32 billion yen through a third-party allotment of new shares with the University of Tokyo Edge Capital Partners as the lead investor and venture capital and business companies as the underwriters. In addition to the Series B-1 round completed in April 2020, the company raised approximately 890 million yen in the B-2 round.

Purpose and Background of Fundraising

Since its inception in 2016, Methuselah has been engaged in the research and development of new cell therapies for heart failure. Our lead asset, MTC001, is a cell therapy using VCAM1-positive cardiac fibroblasts (VCFs) and has confirmed favorable therapeutic effects, such as promoting regeneration of damaged heart tissue, in preclinical studies.
Through this financing, Methuselah will further strengthen its capacity to conduct Phase I clinical trials of MTC001, a cell therapy with a workflow that reduces the burden on medical institutions and a simple manufacturing process. By manufacturing from minimally invasive tissue harvested from the patient's own heart, MTC001 has a significant advantage over other technologies in terms of manufacturing and safety. The achievement of this financing is a major milestone for the future growth of the company, which will strongly promote the efficiency of the manufacturing process, creation of subsequent pipelines, and strategic alliances with academia and companies, with a view to global expansion.

UTEC Partner and Director Atsushi Usami comments:

We are pleased to support Methuselah at this time of its major expansion. Methuselah's approach to science and business, combined with its innovative technology, strong team, and UTEC's investment strategy of focusing on solving global human problems, make this the largest initial investment we have made to date. The speed of development of VCF, which until just five years ago was an academic project, has been phenomenal, and we look forward to working closely with the Methuselah team in the future."

Hiroaki Kobayashi, Principal, UTEC, comments:

As an emergency intensivist, I have treated numerous patients suffering from myocardial infarction and heart failure and have witnessed firsthand the devastating impact on patients, families, and society. Despite the increasing number of patients worldwide, treatment options remain limited and innovation beyond drug therapy is desperately needed. As Methuselah prepares to launch its first clinical trial in patients in early 2021, the timing is right to take a major step toward bringing an innovative product to market. We will continue to fully support Team Methuselah's challenge, believing that the company will be highly regarded not only in Japan but around the world."

Appointment of New Outside Corporate Auditors and Outside Directors

Atsushi Usami, a director and partner of UTEC, was newly appointed as an outside auditor, and Hiroaki Kobayashi, also a principal of UTEC, was appointed as an outside director.

About Atsushi Usami

He has been in charge of seed/early stage investments, mainly in the life science field, and has been a JST START project promoter, a NEDO TCP mentor, and a lecturer at the University of Tokyo's Life Innovation Leading Graduate School Colloquium on industry-academia collaboration. Prior to joining UTEC, he worked at Mitsubishi Research Institute, Inc.

About Hiroaki Kobayashi

After graduating from the University of Tokyo Faculty of Medicine, he worked as an emergency intensivist at the same university hospital and Hitachi General Hospital, Hitachi, Ltd. After working at Japan Organization for Medical Device Development (JOMDD), he studied at the University of Michigan Graduate School of Business Administration (MBA) as a Fulbright Scholar. After returning to Japan, he worked in the Business Development Division of a major medical device manufacturer before joining UTEC in August 2019.

List of underwriters for Series B-2 round (in no particular order)

The University of Tokyo Edge Capital Partners
Alfresa Corporation
The Dai-ichi Life Insurance Co.
KSP Corporation
MAKOTO CAPITAL

Overview of Series B-2 Underwriters

<The University of Tokyo Edge Capital Partners Outline
The University of Tokyo Edge Capital Corporation/University of Tokyo Edge Capital Partners (UTEC) is a venture capital firm that invests in venture companies that utilize the outstanding intellectual property and human resources of the University of Tokyo and other universities and research institutions. Since 2004, UTEC has established and managed four venture capital funds (totaling approximately 55 billion yen as of December 2020), supporting startups based on science and advanced technology, including those from the University of Tokyo.

<Outline of Alfresa Corporation
Alfresa has a social mission to deliver "safe, secure, and high-quality" pharmaceuticals and other products needed when, in the quantities, and to the places where they are needed. Within the Alfresa Group, which has a distribution platform covering all of Japan, there are approximately 180 sales offices in Hokkaido, Tokyo, Nagoya, Osaka, Koshinetsu, and Kyushu, and a total of 2,000 pharmaceutical and medical sales representatives and medical engineers are engaged in sales activities to medical institutions. In addition to a "full lineup" of almost all domestic and overseas manufacturers of pharmaceuticals, reagents, and medical devices, and a "thorough quality control and safe and secure delivery system" to support this lineup, the company is working to respond flexibly and immediately to diverse needs through its high-quality "information provision capabilities.

<Outline of Dai-ichi Life Insurance Co.
The Dai-ichi Life Insurance Company, Limited, was founded in 1902 as Japan's first mutual company. Since then, the company has constantly challenged itself to make changes for the benefit of its customers and society, including becoming the first major life insurance company in Japan to be incorporated as a joint stock company in 2010, and transitioning to a holding company structure in 2016. The company also has an aspect of being an institutional investor, managing approximately 36 trillion yen in assets. In light of the liability characteristics of life insurance policies, the company is actively promoting ESG investments with the aim of both improving investment profitability and resolving social issues, while maintaining its basic ALM approach, which focuses on fixed-income assets. As part of its ESG investment activities, the company is actively making impact investments in venture companies in fields that are highly compatible with its life insurance business, such as medical, healthcare, and fintech, with the aim of both generating investment income and creating a social impact.

<Outline of KSP Inc.
KSP Corporation, the core of the Kanagawa Science Park (KSP), is working to create new industries through the fostering and incubation of venture companies. The company provides support according to growth stage at each stage from start-up to business growth and IPO, and promotes business development that promotes the production of high value-added venture companies that meet the needs of the times. KSP's funds invest in high-tech ventures that are expected to grow rapidly, mainly in the early stages. The current investment in Methuselah Corporation is being made from KSP6 Investment Limited Partnership, which was formed in January 2020.

<Outline of MAKOTO CAPITAL
MAKOTO Capital is a professional firm within the MAKOTO Group, a business creation company based in Sendai City. Under the slogan of "Growth from Tohoku," MAKOTO Capital currently operates a fund business, an accelerator business, and a management consulting business. MAKOTO CAPITAL's overriding mission is to build an ecosystem of business creation and growth in Tohoku by supporting entrepreneurs and companies operating in the region, and to create a Tohoku that can be proud to be part of the world.

About MTC001

MTC001 is a combination product that combines autologous cardiac fibroblasts (VCAM1-positive cardiac fibroblasts, VCF) with a novel catheter for administration. This product has two major advantages over other cell therapies: (1) it is an autologous cell and is organ-derived, making it ideal for highly immune-responsive organs such as the heart, and (2) the minimally invasive catheter specifically designed for VCF administration ensures reliable and safe delivery of cells.

name of companyMethuselah Corporation
EstablishmentMarch 2016
capital stockTsuruoka City, Yamagata Prefecture
representativeTakahiro Iwamiya, Kenichi Nogami
Business OverviewResearch and development of treatment methods for heart disease using fibroblasts
uniform resouce locatorhttps://www.metcela.com/
PORT Editorial Officehttps://port.creww.me/
PORT by Creww is an open innovation media for startups, entrepreneurs, entrepreneurs in recovery, and companies seeking to create new businesses on the theme of social issues, operated by Creww Co.
- Advertisment -
- Advertisment -

Featured

東芝のオープンイノベーション、協業検討に進む2社が決定 ダイナミックマッププラットフォームとArithmerを選定

ReGACY Innovation Group株式会社(東京都千代田区)は、企画・運営パートナーとして支援する株式会社東芝の「Toshiba OPEN INNOVATION PROGRAM 2026」で、協業検討に進む参加企業2社が決定したと発表した。7月に募集した共創プランの中から、ダイナミックマッププラットフォーム株式会社とArithmer株式会社を選定。両社は東芝グループの「Hybrid-3D LiDAR」と「気象データサービス」を活用し、物流・インフラ分野などでの新たなソリューション共創を目指す。12月中旬の成果発表会に向け、実証と事業性検証を進める。 本プログラムでは、2026年7月6日から7月26日まで参加企業を募集しており、応募のあった共創プランの中から、ダイナミックマッププラットフォーム株式会社、Arithmer株式会社の2社が選定されました。 両社は、東芝グループが保有する「Hybrid-3D LiDAR」および「気象データサービス」の技術・データを用いて、物流・インフラ分野やデータ活用領域における新たなビジネスソリューションの共創を目指します。 今後は、12月中旬に予定されている成果発表会に向けて実証や事業性検証を進めるとともに、事業化を見据えた協業の検討を加速していきます。

新潟日報社、オープンイノベーションプログラム2026ピッチ審査会で「三ツ目」「想ひ人」2社を選定

新潟日報社は8月4日、「新潟日報社 オープンイノベーションプログラム2026 ピッチ審査会」を開催した。Creww株式会社が提供する「Creww Growth」を活用し、5月15日から6月15日にかけて新潟県や社会が抱える課題解決に向けた協業アイデアを募集。応募61件の中から書類審査を通過した8社がピッチに参加し、審査の結果「三ツ目」(新潟県三条市)と「想ひ人」(東京都)の2社を選定した。今後は実証事業等を通じて事業化を進める予定。

【ヤマサキ × BeeInventor】高温下での過酷な作業環境から、データは命を守れるか——創業151年の工業炉建設会社とスマートヘルメット新興企業が挑む「熱中症ゼロ」の現場

明治8年創業の株式会社ヤマサキは、建設業界向けアクセラレータープログラム「ヤマサキ×オープンイノベーションプログラム2024」を通じて、スマートヘルメットを手がけるビーインベンターとのPoCを実施した。内部温度800度を超える製鉄炉の傍らで働く現場作業員の熱中症リスクをAIで早期検知するという挑戦は、今まさに第2フェーズへと移行しようとしている。プロジェクトリーダーの向井裕一氏と、BeeInventor(ビーインベンター)のNao SeoChon氏に話を伺った。

【ヤマサキ × CHAOSRU】「誰も知らない技術」を、誰もが体験できる価値へ——創業151年の工業炉建設会社とVRスタートアップが挑む、採用×認知の壁の壊し方

明治8年創業の株式会社ヤマサキは、製鉄に欠かせない築炉の技術を持ちながら、業界・企業の認知度の壁が採用の課題となっていた。この課題の突破口を探るべく参加したのが、『ヤマサキ×オープンイノベーションプログラム2024』だ。プログラムを通じて、VR・XR技術を核とする株式会社CHAOSRUとの協業をスタート。2025年7月から始まったPoC(実証実験)では、高校生向け採用説明会へのVR体験の導入により、ブース来訪者数に明らかな変化が生まれている。アクセラレータープログラムを通じたスタートアップとの協業で何が動き、何が見えてきたのか。株式会社ヤマサキのプロジェクトリーダー 田中敏彦氏と、CHAOSRU代表取締役の内藤薫氏に話を伺った。